2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, Immunotherapy, Artificial Intelligence (AI), Deep Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Diseases, Immunology, Neutropenia, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly
PAPER

3919 MeziKd shows superior immune activity associated with efficacy over Kd from the SUCCESSOR-2 study

Tracy T. Chow, PhD, Keyur Desai2, Zehua Zhou3, Soo Jeong Hwang, PharmD4, Brian Yu5, Phillip Koo6, Alberto Rocci7, Jessica Katz, MD, PhD8, Anita Gandhi, PhD9, Donna Reece, M.D.10, Meletios-Athanasios (Thanos) C. Dimopoulos, MD11, Cesar Gomez12, Chengcheng Fu, MD, PhD13, Fredrik Schjesvold, MD,PhD14, Michael Amatangelo, PhD15, Patrick Hagner16, Paul G. Richardson, MD17
1 Bristol Myers Squibb, Princeton, New Jersey, United States
2 Bristol Myers Squibb, Princeton, New Jersey, United States
3 Bristol Myers Squibb, Princeton, New Jersey, United States
4 Bristol Myers Squibb, Princeton, New Jersey, United States
5 Bristol Myers Squibb, Princeton, New Jersey, United States
6 Bristol Myers Squibb, Princeton, New Jersey, United States
7 Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland
8 Bristol Myers Squibb, Princeton, New Jersey, United States
9 Bristol Myers Squibb, Princeton, New Jersey, United States
10 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
11 National and Kapodistrian University of Athens, Athens, Greece
12 Department of Haematology, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom
13 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China
14 Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway
15 Bristol Myers Squibb, Princeton, New Jersey, United States
16 Bristol Myers Squibb, Princeton, New Jersey, United States
17 Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Introduction: Mezigdomide (Mezi) is an oral CELMoD agent that promotes cereblon–mediated degradation of the transcription factors Aiolos and Ikaros, driving direct tumoricidal and immunomodulatory activity in multiple myeloma (MM). The phase 3 SUCCESSOR-2 study (NCT05552976) evaluates Mezi plus carfilzomib and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory MM (RRMM) and showed significantly improved progression-free survival (PFS) with MeziKd vs Kd (Dimopoulos M et al. Lancet 2026). To better understand the immunomodulatory mechanism of Mezi and its relationship to clinical efficacy, we performed longitudinal immune biomarker profiling of peripheral blood and evaluated associations of early on-treatment immune changes with response across various subgroups.

Methods: Peripheral blood immunophenotyping was performed by flow cytometry at cycle (C)1 day (D)1, C1D15, C3D1, C3D15 and end of treatment (EOT) in stage 1 biomarker subgroups. Treatment-arm comparisons focused on 1.0 mg MeziKd (n=38) versus Kd (n=27) cohorts. Efficacy-association analyses of C1D15 immune changes with PFS and response (≥partial response [PR]) were evaluated in pooled stage 1 MeziKd immune-evaluable patients across 1.0 mg, 0.6 mg, and 0.3 mg using univariate models (PFS n=86, 51 events, Cox proportional hazards; ≥PR n=85, 65 responders, logistic regression) and Kaplan-Meier analyses with log-rank test. Subgroup analyses included high-risk, soft tissue plasmacytomas, prior therapy exposure/refractoriness, and later-line populations.

Results: Among the immune biomarker subcohorts, baseline characteristics were broadly balanced among MeziKd (1.0 mg n=38; 0.6 mg n=37; 0.3 mg n=43) and Kd (n=27) in patients exposed to lenalidomide and anti-CD38 monoclonal antibody with high refractory burden. Compared with Kd, MeziKd induced deeper peripheral B-cell depletion by C1D15 (Median %change in MeziKd -93% vs Kd -25%), with separation narrowing by EOT. MeziKd also produced greater coordinated T-cell immune modulation than Kd across CD4+ and CD8+ subsets, including decreases in naïve T-cells (Median %change CD4+ MeziKd -55% vs Kd 23%; CD8+ MeziKd -41% vs Kd 37%) and increases in proliferative (Median %change CD4+ MeziKd 305% vs Kd -19%; CD8+ MeziKd 513% vs Kd 85%), effector-memory (Median %change CD4+ MeziKd 52% vs Kd -11%; CD8+ MeziKd 136% vs Kd 2%), and activated T cells (Median %change CD4+ MeziKd 143% vs Kd -22%; CD8+ MeziKd 41% vs Kd 1%). These changes generally peaked at mid-cycle1 and regressed toward baseline by EOT, consistent with the reversible on-treatment immune modulatory effects of Mezi.

Among pooled MeziKd immune-evaluable patients, early (C1D15) immune modulation was associated with clinical outcomes. Deeper B-cell depletion and increased proliferative CD4+ T-cells were significantly associated with both prolonged PFS (HR=0.75, P=0.016 per 1 standard deviation [SD] decrease and HR=0.66 P=0.035 per 1 SD increase, respectively) and improved response outcomes (P<0.05), with additional markers uniquely associated with ≥PR including decrease in naïve and increase in activated HLA-DR+ CD4+ T-cells (P<0.05). Kaplan-Meier analyses by tertile cut points showed that deeper reduction of naïve CD4+ T-cells and larger increase in early CD4+ T-cell activation/proliferation separated longer PFS groups (P=0.007–0.042), while deeper early B-cell depletion showed the strongest PFS separation (P=0.005). Moreover, MeziKd-mediated CD4+ T-cell proliferation/activation was preserved across patients with cytogenetic high-risk, soft tissue plasmacytomas, later-line (3+ pLOT [prior line of treatment]), and prior therapy subgroups, including anti-CD38 and/or pomalidomide-refractory populations, and signals were retained in the limited number of patients with prior exposure to T-cell redirecting therapies.

Conclusions: MeziKd elicited deeper and more consistent immune activation by early mid-cycle 1 beyond that observed with Kd, including coordinated B- and T-cell modulation associated with improved clinical efficacy, suggesting Mezi-mediated immune activity contributes to superior clinical response observed with MeziKd. Persistent MeziKd-mediated immune activity across high-risk subgroups, irrespective of prior therapies, supports MeziKd as a potent and differentiated option in early-relapsed RRMM. Additional Mezi-based combination strategies are under investigation across MM populations.

Tracy T. Chow, PhD: Bristol Myers Squibb - Current equity holder in publicly-traded company; Bristol Myers Squibb - Current Employment